Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT00883753
Registration number
NCT00883753
Ethics application status
Date submitted
17/04/2009
Date registered
20/04/2009
Date last updated
6/08/2014
Titles & IDs
Public title
An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy
Query!
Scientific title
An Extension Phase of the Multi-National Open-Label Study (MA21573) to Evaluate the Safety, Tolerability and Efficacy of Tocilizumab in Patients With Active Rheumatoid Arthritis on Background Non-biologic DMARDs Who Have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.
Query!
Secondary ID [1]
0
0
2008-006924-68
Query!
Secondary ID [2]
0
0
MA22460
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Rheumatoid Arthritis
0
0
Query!
Condition category
Condition code
Musculoskeletal
0
0
0
0
Query!
Osteoarthritis
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - tocilizumab [RoActemra/Actemra]
Experimental: tocilizumab - Participants received tocilizumab 8 mg/kg intravenous (IV), maximum dose not exceeding 800 mg in a single infusion, every 4 weeks for up to 104 weeks or up to 4 weeks after tocilizumab became commercially available in the respective country whichever occurred first.
Treatment: Drugs: tocilizumab [RoActemra/Actemra]
8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Query!
Assessment method [1]
0
0
An AE was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. A SAE was any experience that: resulted in death, was life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect or was medically significant. The percentage of participants with AEs and SAEs that occurred in the Extension Study grouped according to the number of disease-modifying anti-rheumatic drugs (DMARD) a participant was taking at Core Baseline is presented.
Query!
Timepoint [1]
0
0
108 Weeks
Query!
Secondary outcome [1]
0
0
Percentage of Participants With Adverse Events Leading to Withdraw
Query!
Assessment method [1]
0
0
An Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events.
Query!
Timepoint [1]
0
0
108 Weeks
Query!
Secondary outcome [2]
0
0
Time to Withdrawal Due to an Adverse Event (AE)
Query!
Assessment method [2]
0
0
Time to withdrawal was defined as the number of days from Core Study Day 1 to the first date of onset of the AE leading to discontinuation of tocilizumab.
Query!
Timepoint [2]
0
0
108 Weeks
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Discontinuation of Treatment Due to Any Cause
Query!
Assessment method [3]
0
0
Percentage of participants who discontinued treatment with tocilizumab for any reason.
Query!
Timepoint [3]
0
0
108 Weeks
Query!
Secondary outcome [4]
0
0
Time to Discontinuation of Tocilizumab Treatment for Any Cause
Query!
Assessment method [4]
0
0
Time in days from start of the Core Study Day 1 to discontinuation of tocilizumab for any reason.
Query!
Timepoint [4]
0
0
108 Weeks
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Marked Lipid Abnormalities
Query!
Assessment method [5]
0
0
Fasting blood samples were collected for Lipids: Cholesterol, Triglyceride, High-density lipoprotein (HDL) Cholesterol, Low-density lipoprotein (LDL) Cholesterol every 12 weeks and at follow-up in the Extension study and were sent to a central laboratory for analysis. Lipid abnormalities were defined as a High Cholesterol, High Triglyceride, Low HDL Cholesterol and a High LDL Cholesterol that occurred at any time in the extension study.
Query!
Timepoint [5]
0
0
108 Weeks
Query!
Secondary outcome [6]
0
0
Percentage of Participants With Adverse Events (AEs) of Special Interest
Query!
Assessment method [6]
0
0
An Adverse Event was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. Preexisting conditions that worsened during the study and laboratory or clinical tests that resulted in a change in treatment or discontinuation from study drug were reported as adverse events. Adverse Events of special interest for this study were: Infections (preferred term in the infection adverse event group term), Serious Infections (an infection that qualified as Serious Adverse Event), Infusion Reactions (occurred during infusion or within 24 hours of infusion), Major Cardiac AE (Myocardial Infarction/ Acute Coronary Syndrome), Stroke or Death.
Query!
Timepoint [6]
0
0
108 Weeks
Query!
Secondary outcome [7]
0
0
Percentage of Participants With ALT Elevations > 3*ULN
Query!
Assessment method [7]
0
0
Blood samples were collected for the Liver Function Test: Alanine aminotransferase (ALT) every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. Percentage of participants with any values greater than 3 times the Upper Limit of Normal (3*ULN) is reported. ULN= 55 Units/Liter.
Query!
Timepoint [7]
0
0
108 Weeks
Query!
Secondary outcome [8]
0
0
Percentage of Participants With AST Elevations > 3*ULN
Query!
Assessment method [8]
0
0
Blood was collected for the Liver Function Test: Aspartate aminotransferase (AST) every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. Percentage of participants with any values greater than 3 times the Upper Limit of Normal (3*ULN) is reported. ULN= 40 Units/Liter.
Query!
Timepoint [8]
0
0
108 Weeks
Query!
Secondary outcome [9]
0
0
Number of Participants Categorized by Highest Value for ALT (SGPT) During the Study
Query!
Assessment method [9]
0
0
Blood samples were collected for liver function test: Alanine aminotransferase (serum glutamic-pyruvic transaminase) [ALT(SGPT)] every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. The Upper Limit of Normal (ULN) for ALT=55 Units/Liter. The number of participants categorized by the highest value for ALT/GPT during the study is reported: Normal (ALT result within the central lab reference range), Greater than the ULN to 1.5 times the ULN (>ULN to 1.5*ULN), 1.5 times the ULN to 3 times the ULN (1.5*ULN to 3*ULN) and 3 times the ULN to 5 times the ULN (3*ULN to 5*ULN).
Query!
Timepoint [9]
0
0
108 Weeks
Query!
Secondary outcome [10]
0
0
Number of Participants Categorized by Worst Value for AST (SGOT) During the Study
Query!
Assessment method [10]
0
0
Blood samples were collected for liver function test: Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase) [AST (SGOT)] every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. The Upper Limit of Normal (ULN) for AST=40 Units/Liter. The number of participants categorized by worst value for AST(SGOT) during the study is reported: Normal (AST result is within the central lab reference range), Greater than the ULN to 1.5 times the ULN (>ULN to 1.5*ULN), 1.5 times the ULN to 3 times the ULN (1.5*ULN to 3*ULN) and 3 times the ULN to 5 times the ULN (3*ULN to 5*ULN).
Query!
Timepoint [10]
0
0
108 Weeks
Query!
Secondary outcome [11]
0
0
Number of Participants Categorized by Worst Value for LDL Cholesterol During the Study
Query!
Assessment method [11]
0
0
Blood samples were collected for LDL Cholesterol every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. The number of participants categorized by the worst value for LDL Cholesterol during the study is reported: Low is below central lab reference range, Normal is within the central lab reference range and High is above central lab reference range.
Query!
Timepoint [11]
0
0
108 Weeks
Query!
Secondary outcome [12]
0
0
Number of Participants Categorized by Worst Value for Total Cholesterol During the Study
Query!
Assessment method [12]
0
0
Blood samples were collected for Total Cholesterol every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. The number of participants categorized by worst value for Total Cholesterol during the study is reported: Low is below central lab reference range, Normal is within the central lab reference range and High is above central lab reference range.
Query!
Timepoint [12]
0
0
108 Weeks
Query!
Secondary outcome [13]
0
0
Number of Participants Categorized by Worst Value for Neutrophil Count During the Study
Query!
Assessment method [13]
0
0
Blood samples were collected for a Neutrophil Count every 12 weeks and at the follow-up visit in the Extension study and were sent to a central laboratory for analysis. The number of participants categorized by the worst value for Neutrophil Count during the study is reported: Low is below central lab reference range, Normal is within the central lab reference range and High is above central lab reference range.
Query!
Timepoint [13]
0
0
108 Weeks
Query!
Secondary outcome [14]
0
0
Percentage of Participants With Clinically Meaningful Improvement in Disease Activity Score-28 (DAS28)
Query!
Assessment method [14]
0
0
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. Clinical meaningful improvement was defined as a = 1.2 unit reduction in DAS28.
Query!
Timepoint [14]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [15]
0
0
Percentage of Participants With DAS28 Low Disease Activity
Query!
Assessment method [15]
0
0
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. Low Disease Activity was defined as a score of < 3.2.
Query!
Timepoint [15]
0
0
Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [16]
0
0
Percentage of Participants With DAS28 Remission
Query!
Assessment method [16]
0
0
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. DAS28 Remission was defined as a DAS28 score < 2.6.
Query!
Timepoint [16]
0
0
Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [17]
0
0
Change From Baseline in DAS28
Query!
Assessment method [17]
0
0
The DAS28 score is a measure of the patient's disease activity calculated using the tender joint count (TJC) [28 joints], swollen joint count (SJC) [28 joints], patient's global assessment of disease activity [visual analog scale: 0=no disease activity to 100=maximum disease activity] and the erythrocyte sedimentation rate (ESR) for a total possible score of 0 to approximately 10. Scores below 2.6 indicate best disease control and scores above 5.1 indicate worse disease control. A negative change from Baseline indicated improvement.
Query!
Timepoint [17]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [18]
0
0
Change From Baseline in Tender Joint Count
Query!
Assessment method [18]
0
0
68 joints were assessed for tenderness and joints were classified as tender/not tender giving a total possible tender joint count score of 0 to 68. A negative change from Baseline indicated improvement.
Query!
Timepoint [18]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [19]
0
0
Change From Baseline in Swollen Joint Count
Query!
Assessment method [19]
0
0
66 joints were assessed for swelling and joints were classified as swollen/not swollen giving a total possible swollen joint count score of 0 to 66. A negative change from Baseline indicated improvement.
Query!
Timepoint [19]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [20]
0
0
Change From Baseline in Patient Assessment of Pain Visual Analog Scale (VAS)
Query!
Assessment method [20]
0
0
The patient assessed their pain using a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS). The left-hand extreme of the line equals 0 mm, and is described as "no pain" and the right-hand extreme equals 100 mm as "unbearable pain". A negative change from Baseline indicated improvement.
Query!
Timepoint [20]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [21]
0
0
Change From Baseline in Patient Global Assessment of Disease Activity VAS
Query!
Assessment method [21]
0
0
The patients global assessment of disease activity was assessed on a 0 to 100 millimeter (mm) horizontal visual analogue scale (VAS) by the patient. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Query!
Timepoint [21]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [22]
0
0
Change From Baseline in Physician Global Assessment of Disease Activity VAS
Query!
Assessment method [22]
0
0
The physician global assessment of disease activity was assessed using a 0 to 100 mm horizontal visual analogue scale (VAS) by the physician. The left-hand extreme of the line equals 0 mm, and is described as "no disease activity" (symptom-free and no arthritis symptoms) and the right-hand extreme equals 100 mm, as "maximum disease activity" (maximum arthritis disease activity). A negative change from Baseline indicated improvement.
Query!
Timepoint [22]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [23]
0
0
Change From Baseline in Erythrocyte Sedimentation Rate (ESR)
Query!
Assessment method [23]
0
0
Blood was collected for Erythrocyte Sedimentation Rate (ESR) (a test that assesses tissue inflammation) and was analyzed at a local laboratory. ESR was measured in millimeters/hour (mm/hr). A reduction in the level is considered an improvement.
Query!
Timepoint [23]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [24]
0
0
Change From Baseline in C-Reactive Protein (CRP)
Query!
Assessment method [24]
0
0
Blood was collected for C-Reactive Protein (CRP) (a test for analysis of inflammatory and infectious disorders) and was analyzed at a central laboratory. The serum concentration of CRP was measured in milligrams/deciliter (mg/dL). A reduction in the level is considered an improvement.
Query!
Timepoint [24]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [25]
0
0
Percentage of Participants With American College of Rheumatology 20 (ACR20) Response
Query!
Assessment method [25]
0
0
ACR20 response was defined as a = 20 % improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Query!
Timepoint [25]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [26]
0
0
Percentage of Participants With American College of Rheumatology 50 (ACR50) Response
Query!
Assessment method [26]
0
0
ACR50 response is defined as a = 50 % improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Query!
Timepoint [26]
0
0
Core Baseline, Extension Weeks 12, 24, 36, 48, 60, 72, 84, 96, 108
Query!
Secondary outcome [27]
0
0
Percentage of Participants With American College of Rheumatology 70 (ACR70) Response
Query!
Assessment method [27]
0
0
ACR70 response is defined as a = 70 % improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Query!
Timepoint [27]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [28]
0
0
Percentage of Participants With American College of Rheumatology 90 (ACR90) Response
Query!
Assessment method [28]
0
0
ACR90 response is defined as a = 90 % improvement (reduction) compared with baseline for both total joint count-68 joints (TJC68) and swollen joint count-66 joints (SJC66), as well as for three of the additional five ACR core set variables: Patient's Assessment of Pain over the previous 24 hours: using a Visual Analog Scale (VAS) left end of the line 0=no pain to right end of the line 100=unbearable pain; Patient's Global Assessment of Disease Activity and Physician's Global Assessment of Disease Activity over the previous 24 hours using a VAS where left end of the line 0=no disease activity to right end of the line 100=maximum disease activity; Health Assessment Questionnaire: 20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities, 0=without difficulty to 3=unable to do; and acute-phase reactant [either C-reactive protein or Erythrocyte Sedimentation Rate].
Query!
Timepoint [28]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [29]
0
0
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Response
Query!
Assessment method [29]
0
0
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). A negative change from Baseline indicated improvement.
Query!
Timepoint [29]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [30]
0
0
Percentage of Participants Achieving Clinical Meaningful Health Assessment Questionnaire Disability Index (HAQ-DI) Response
Query!
Assessment method [30]
0
0
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). Clinically meaningful improvement is defined as a reduction from Baseline in the HAQ-DI score = 0.2.
Query!
Timepoint [30]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [31]
0
0
Percentage of Participants Achieving Health Assessment Questionnaire Disability Index (HAQ-DI) Clinical Remission
Query!
Assessment method [31]
0
0
The Stanford Health Assessment Questionnaire Disability Index (HAQ-DI) is a patient completed questionnaire specific for rheumatoid arthritis, consisting of 20 questions in 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. There are 4 possible responses for each question: 0=without any difficulty, 1=with some difficulty, 2=with much difficulty and 3=unable to do. The score for each of the domains is the highest (worst) score in each domain. A patient must have a domain score for at least 6 of 8 domains to calculate a valid HAQ-DI score which is the sum of domain scores, divided by the number of domains that have a score for a total possible score minimum/maximum 0 (best) to 3 (worst). Clinical Remission is defined as a HAQ-DI score < 0.5.
Query!
Timepoint [31]
0
0
Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [32]
0
0
Change From Baseline in Quality of Life Short Form (SF-36): Physical Component Score
Query!
Assessment method [32]
0
0
The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from Baseline indicated improvement.
Query!
Timepoint [32]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [33]
0
0
Change From Baseline in Quality of Life Short Form (SF-36):Mental Component Score
Query!
Assessment method [33]
0
0
The SF-36 is a questionnaire used to assess physical functioning and is made up of eight domains: Physical Functioning, Role Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role-Emotional and Mental Health. Transforming and standardizing these domains leads to the calculation of the Physical (PCS) and Mental (MCS) Component Summary measures. Scores ranging from 0 to 100, with 0=worst score (or quality of life) and 100=best score. A positive change from Baseline indicated improvement.
Query!
Timepoint [33]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Secondary outcome [34]
0
0
Change From Baseline in FACIT-Fatigue Score
Query!
Assessment method [34]
0
0
FACIT-F is a 13-item questionnaire. Patients scored each item on a 5-point scale: 0 (Not at all) to 4 (Very much). The larger the patient's response to the questions (with the exception of 2 negatively stated), the greater the patient's fatigue. For all questions, except for the 2 negatively stated ones, the code was reversed and a new score was calculated as (4 minus the patient's response). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse score) to 52 (better score). A higher score reflects an improvement in the patient's health status. A positive change from Baseline indicated improvement.
Query!
Timepoint [34]
0
0
Core Baseline, Extension Weeks 12, 24, 36 ,48, 60, 72, 84, 96, 108
Query!
Eligibility
Key inclusion criteria
- patients who completed the 24-week MA21573 core study, had at least a moderate response
based on EULAR definition criteria and no adverse events (AEs), serious adverse events
(SAEs) or conditions that led to unacceptable risk of continued treatment.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
-as for MA21573.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/03/2009
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
1/04/2012
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
934
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,VIC
Query!
Recruitment hospital [1]
0
0
- Canberra
Query!
Recruitment hospital [2]
0
0
- Coffs Harbour
Query!
Recruitment hospital [3]
0
0
- Kogarah
Query!
Recruitment hospital [4]
0
0
- Cairns
Query!
Recruitment hospital [5]
0
0
- Adelaide
Query!
Recruitment hospital [6]
0
0
- Fitzroy
Query!
Recruitment hospital [7]
0
0
- Geelong
Query!
Recruitment hospital [8]
0
0
- Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2601 - Canberra
Query!
Recruitment postcode(s) [2]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [3]
0
0
2217 - Kogarah
Query!
Recruitment postcode(s) [4]
0
0
4870 - Cairns
Query!
Recruitment postcode(s) [5]
0
0
5041 - Adelaide
Query!
Recruitment postcode(s) [6]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [7]
0
0
3220 - Geelong
Query!
Recruitment postcode(s) [8]
0
0
3168 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
Canada
Query!
State/province [1]
0
0
Alberta
Query!
Country [2]
0
0
Canada
Query!
State/province [2]
0
0
British Columbia
Query!
Country [3]
0
0
Canada
Query!
State/province [3]
0
0
New Brunswick
Query!
Country [4]
0
0
Canada
Query!
State/province [4]
0
0
Newfoundland and Labrador
Query!
Country [5]
0
0
Canada
Query!
State/province [5]
0
0
Ontario
Query!
Country [6]
0
0
Canada
Query!
State/province [6]
0
0
Quebec
Query!
Country [7]
0
0
Canada
Query!
State/province [7]
0
0
Saskatchewan
Query!
Country [8]
0
0
Czech Republic
Query!
State/province [8]
0
0
Bruntal
Query!
Country [9]
0
0
Czech Republic
Query!
State/province [9]
0
0
Ostrava
Query!
Country [10]
0
0
Czech Republic
Query!
State/province [10]
0
0
Praha
Query!
Country [11]
0
0
Czech Republic
Query!
State/province [11]
0
0
Sokolov
Query!
Country [12]
0
0
Czech Republic
Query!
State/province [12]
0
0
Uherske Hradiste
Query!
Country [13]
0
0
Czech Republic
Query!
State/province [13]
0
0
Zlin
Query!
Country [14]
0
0
France
Query!
State/province [14]
0
0
Belfort
Query!
Country [15]
0
0
France
Query!
State/province [15]
0
0
Caen
Query!
Country [16]
0
0
France
Query!
State/province [16]
0
0
Cahors
Query!
Country [17]
0
0
France
Query!
State/province [17]
0
0
Corbeil-essonnes
Query!
Country [18]
0
0
France
Query!
State/province [18]
0
0
Dijon
Query!
Country [19]
0
0
France
Query!
State/province [19]
0
0
La Rochelle
Query!
Country [20]
0
0
France
Query!
State/province [20]
0
0
Lievin
Query!
Country [21]
0
0
France
Query!
State/province [21]
0
0
Lomme
Query!
Country [22]
0
0
France
Query!
State/province [22]
0
0
Lyon
Query!
Country [23]
0
0
France
Query!
State/province [23]
0
0
Marseille
Query!
Country [24]
0
0
France
Query!
State/province [24]
0
0
Montivilliers
Query!
Country [25]
0
0
France
Query!
State/province [25]
0
0
Montpellier
Query!
Country [26]
0
0
France
Query!
State/province [26]
0
0
Mulhouse
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Paris
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Poitiers
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Reims
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Roubaix
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
St Brieuc
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Strasbourg
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Toulouse
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Valence
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Valenciennes
Query!
Country [36]
0
0
Greece
Query!
State/province [36]
0
0
Heraklion
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Budapest
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Eger
Query!
Country [39]
0
0
Hungary
Query!
State/province [39]
0
0
Szeged
Query!
Country [40]
0
0
Hungary
Query!
State/province [40]
0
0
Veszprem
Query!
Country [41]
0
0
Italy
Query!
State/province [41]
0
0
Arenzano
Query!
Country [42]
0
0
Italy
Query!
State/province [42]
0
0
Legnano
Query!
Country [43]
0
0
Italy
Query!
State/province [43]
0
0
Milano
Query!
Country [44]
0
0
Italy
Query!
State/province [44]
0
0
Modena
Query!
Country [45]
0
0
Italy
Query!
State/province [45]
0
0
Monserrato
Query!
Country [46]
0
0
Italy
Query!
State/province [46]
0
0
Novara
Query!
Country [47]
0
0
Italy
Query!
State/province [47]
0
0
Palermo
Query!
Country [48]
0
0
Italy
Query!
State/province [48]
0
0
Potenza
Query!
Country [49]
0
0
Italy
Query!
State/province [49]
0
0
Roma
Query!
Country [50]
0
0
Italy
Query!
State/province [50]
0
0
Siena
Query!
Country [51]
0
0
Italy
Query!
State/province [51]
0
0
Varese
Query!
Country [52]
0
0
Netherlands
Query!
State/province [52]
0
0
'S Hertogenbosch
Query!
Country [53]
0
0
Netherlands
Query!
State/province [53]
0
0
Alkmaar
Query!
Country [54]
0
0
Netherlands
Query!
State/province [54]
0
0
Amsterdam
Query!
Country [55]
0
0
Netherlands
Query!
State/province [55]
0
0
Apeldoorn
Query!
Country [56]
0
0
Netherlands
Query!
State/province [56]
0
0
Arnhem
Query!
Country [57]
0
0
Netherlands
Query!
State/province [57]
0
0
Bergen Op Zoom
Query!
Country [58]
0
0
Netherlands
Query!
State/province [58]
0
0
Den Haag
Query!
Country [59]
0
0
Netherlands
Query!
State/province [59]
0
0
Den Helder
Query!
Country [60]
0
0
Netherlands
Query!
State/province [60]
0
0
Enschede
Query!
Country [61]
0
0
Netherlands
Query!
State/province [61]
0
0
Gouda
Query!
Country [62]
0
0
Netherlands
Query!
State/province [62]
0
0
Heerlen
Query!
Country [63]
0
0
Netherlands
Query!
State/province [63]
0
0
Hilversum
Query!
Country [64]
0
0
Netherlands
Query!
State/province [64]
0
0
Leeuwarden
Query!
Country [65]
0
0
Netherlands
Query!
State/province [65]
0
0
Nieuwegein
Query!
Country [66]
0
0
Netherlands
Query!
State/province [66]
0
0
Nijmegen
Query!
Country [67]
0
0
Netherlands
Query!
State/province [67]
0
0
Roosendaal
Query!
Country [68]
0
0
Netherlands
Query!
State/province [68]
0
0
Rotterdam
Query!
Country [69]
0
0
Netherlands
Query!
State/province [69]
0
0
Schiedam
Query!
Country [70]
0
0
Netherlands
Query!
State/province [70]
0
0
Spijkenisse
Query!
Country [71]
0
0
Netherlands
Query!
State/province [71]
0
0
Vlissingen
Query!
Country [72]
0
0
Poland
Query!
State/province [72]
0
0
Krakow
Query!
Country [73]
0
0
Poland
Query!
State/province [73]
0
0
Poznan
Query!
Country [74]
0
0
Poland
Query!
State/province [74]
0
0
Wroclaw
Query!
Country [75]
0
0
Portugal
Query!
State/province [75]
0
0
Almada
Query!
Country [76]
0
0
Portugal
Query!
State/province [76]
0
0
Coimbra
Query!
Country [77]
0
0
Portugal
Query!
State/province [77]
0
0
Lisboa
Query!
Country [78]
0
0
Portugal
Query!
State/province [78]
0
0
Porto
Query!
Country [79]
0
0
Romania
Query!
State/province [79]
0
0
Bucharest
Query!
Country [80]
0
0
Romania
Query!
State/province [80]
0
0
Cluj-napoca
Query!
Country [81]
0
0
Saudi Arabia
Query!
State/province [81]
0
0
Jeddah
Query!
Country [82]
0
0
Spain
Query!
State/province [82]
0
0
Alicante
Query!
Country [83]
0
0
Spain
Query!
State/province [83]
0
0
Barcelona
Query!
Country [84]
0
0
Spain
Query!
State/province [84]
0
0
La Coruña
Query!
Country [85]
0
0
Spain
Query!
State/province [85]
0
0
Las Palmas
Query!
Country [86]
0
0
Spain
Query!
State/province [86]
0
0
Tenerife
Query!
Country [87]
0
0
Spain
Query!
State/province [87]
0
0
Almeria
Query!
Country [88]
0
0
Spain
Query!
State/province [88]
0
0
Caceres
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Cordoba
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
Granada
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
Huesca
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Lugo
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Madrid
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Malaga
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Salamanca
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Sevilla
Query!
Country [97]
0
0
Spain
Query!
State/province [97]
0
0
Valencia
Query!
Country [98]
0
0
United Kingdom
Query!
State/province [98]
0
0
Barnsley
Query!
Country [99]
0
0
United Kingdom
Query!
State/province [99]
0
0
Basingstoke
Query!
Country [100]
0
0
United Kingdom
Query!
State/province [100]
0
0
Bournemouth
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Brighton
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Burton on Trent
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
Bury St Edmonds
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Cambridge
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Cardiff
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Chelmsford
Query!
Country [107]
0
0
United Kingdom
Query!
State/province [107]
0
0
Dudley
Query!
Country [108]
0
0
United Kingdom
Query!
State/province [108]
0
0
Eastbourne
Query!
Country [109]
0
0
United Kingdom
Query!
State/province [109]
0
0
Gillingham
Query!
Country [110]
0
0
United Kingdom
Query!
State/province [110]
0
0
Harrogate
Query!
Country [111]
0
0
United Kingdom
Query!
State/province [111]
0
0
Ipswich
Query!
Country [112]
0
0
United Kingdom
Query!
State/province [112]
0
0
Liverpool
Query!
Country [113]
0
0
United Kingdom
Query!
State/province [113]
0
0
Llantrisant
Query!
Country [114]
0
0
United Kingdom
Query!
State/province [114]
0
0
Londonderry
Query!
Country [115]
0
0
United Kingdom
Query!
State/province [115]
0
0
London
Query!
Country [116]
0
0
United Kingdom
Query!
State/province [116]
0
0
Maidstone
Query!
Country [117]
0
0
United Kingdom
Query!
State/province [117]
0
0
Middlesborough
Query!
Country [118]
0
0
United Kingdom
Query!
State/province [118]
0
0
Newcastle Upon Tyne
Query!
Country [119]
0
0
United Kingdom
Query!
State/province [119]
0
0
Nottingham
Query!
Country [120]
0
0
United Kingdom
Query!
State/province [120]
0
0
Reading
Query!
Country [121]
0
0
United Kingdom
Query!
State/province [121]
0
0
Salford
Query!
Country [122]
0
0
United Kingdom
Query!
State/province [122]
0
0
Sheffield
Query!
Country [123]
0
0
United Kingdom
Query!
State/province [123]
0
0
Southport
Query!
Country [124]
0
0
United Kingdom
Query!
State/province [124]
0
0
Swindon
Query!
Country [125]
0
0
United Kingdom
Query!
State/province [125]
0
0
Torquay
Query!
Country [126]
0
0
United Kingdom
Query!
State/province [126]
0
0
Westcliffe-on-sea
Query!
Country [127]
0
0
United Kingdom
Query!
State/province [127]
0
0
Wirral
Query!
Country [128]
0
0
United Kingdom
Query!
State/province [128]
0
0
Worthing
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Hoffmann-La Roche
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This study was an extension to study MA21573 [NCT00750880], which was an open label single
arm study to investigate the safety, tolerability and efficacy of tocilizumab monotherapy, or
combination therapy with non-biological disease-modifying antirheumatic drugs (DMARDS), in
patients with moderate to severe active rheumatoid arthritis. Patients who completed the 24
week core study, and had at least a moderate European League Against Rheumatism (EULAR)
response, were eligible to enter this long-term extension study, and received tocilizumab 8
mg/kg intravenous (iv) every 4 weeks. The anticipated time on study treatment was 1-2 years,
and the target sample size was > 500 individuals.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT00883753
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Trials
Query!
Address
0
0
Hoffmann-La Roche
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT00883753
Download to PDF